Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AVEO Oncology provides update on interim analysis from Tivozanib trial in colorectal cancer


Friday, 13 Dec 2013 06:50am EST 

AVEO Oncology:Says the data from a planned interim analysis of the Phase two BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.BATON-CRC, led by Astellas, is an open-label, randomized Phase two study with a primary endpoint evaluating the superiority of tivozanib in combination with modified FOLFOX6.Says data from the planned interim analysis, including biomarker data, are being analyzed, and AVEO and Astellas are in discussions regarding next steps. 

Related Company News

Company Quote

1.37
0.01 +0.74%
27 Mar 2015